08 Labeling Chemistry

Peroxidase Labeling Kit - SH

Peroxidase Labeling Kit - SH

Antibody / Protein Labeling

  • It takes only 3 hours to recover conjugates
  • All processes in a single Filtration tube
  • High recovery of conjugates
  • Product code
    LK09  Peroxidase Labeling Kit - SH
Unit size Price Item Code
3 samples $223.00 LK09-10
Order
3 samples
Quantity may be adjusted within the cart.
Component
3 samples ・SH-Reactive Peroxidase
・Reducing Agent
・Solution A
・Solution B
・Reaction Buffer
・Storage Buffer
・Filtration Tube
3 tubes
3 tubes
4 ml x1
1 ml x1
200 μl x1
4 ml x1
3 tubes

Description

Peroxidase Labeling Kit-SH is used mainly for the preparation of peroxidase-labeled IgG for enzyme immunoassay (EIA) and for the preparation of peroxidase-labeled antigen for competitive EIA. SH-reactive peroxidase, a component of this kit, can react with the thiol groups of proteins or other molecules (Fig. 1). This kit contains all the necessary reagents for the labeling process, including reducing agent and storage buffer. SH-reactive peroxidase forms a covalent link with the target molecule. Reducing agent can create free thiol groups in the IgG molecule. When peroxidase-labeled IgG is used for EIA, the labeling efficiency of the SH-reactive peroxidase is high enough to eliminate any postlabeling purification process.. If a high-purity conjugate is required after labeling, simply use an affinity column or a gelpermeation column. When labeling small molecules, excess molecules can be removed by using the filtration tubes included in this kit.


Fig. 1 IgG labeling reaction of SH-reactive peroxidase

Precaution
♦ The molecular weight of the reduced protein to be labeled with this kit should be greater than 50,000.
♦ The molecular weight of the small thiol compound to be labeled with this kit should be smaller than 5,000.
♦ IgG or peroxidase-conjugated IgG is always on the membrane of the filtration tube during the labeling process.
♦ If the IgG solution contains other proteins with molecular weight larger than 10,000, such as BSA or gelatin, purify the IgG solution prior to labeling peroxidase with this kit. 
♦ If the IgG solution contains small insoluble materials, centrifuge the solution and use the supernatant for the labeling.

Developer Dojindo Molecular Technologies, Inc.

Manual

Technical info


Fig. 2 Sandwich ELISA of human TNF-α detection

Plate: 2 μg/ml anti-human TNF-aantibody (rabbit, polyclonal)-coated high binding plate
recombinant human TNF-a: 0-1000 pg/ml PBST
Peroxidase-conjugated anti-human TNF-aantibody: Prepared by Peroxidase Labeling Kit-SH.1μg/ml
PBST+blocking reagent
Substrate: TMB peroxidase substrate

References
1. K. Inoue, A. Sugiyama, P. C. Reid, Y, Ito, K. Miyauchi, S. Mukai, M. Sagara, K. Miyamoto, H. Satoh, I. Kohno, T. Kurata, H. Ota, A. Mantovani, T. Hamakubo, H. Daida and T. Kodama, Establishment of a High Sensitivity Plasma Assay for Human Pentraxin3 as a Marker for Unstable Angina Pectoris, Arterioscler. Thromb. Vasc. Biol., 2007, 27, 161

References

Open References

1) K. Inoue, A. Sugiyama, P. C. Reid, Y. Ito, K. Miyauchi, S. Mukai, M. Sagara, K. Miyamoto, H. Satoh, I. Kohno, T. Kurata, H. Ota, A. Mantovani, T. Hamakubo, H. Daida and T. Kodama, "Establishment of a High Sensitivity Plasma Assay for Human Pentraxin3 as a Marker for Unstable Angina Pectoris", Arterioscler. Thromb. Vasc. Biol., 200727, 161.
2) N. Esaki, Y. Ohkawa, N. Hashimoto, Y. Tsuda, Y. Ohmi, R. H. Bhuiyan, N. Kotani, K. Honke, A. Enomoto, M. Takahashi, K. Furukawa, and K. Furukawa, "ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer."Cancer Sci.., 2018, 109, (1), 141.
3) G.W.Zhanga, S.J.Lai, Y.Yoshimura, and N.Isobe, "Messenger RNA expression and immunolocalization of psoriasin in the goat mammary gland and its milk concentration after an intramammary infusion of lipopolysaccharide"Vet. J.., 2014, 202, (1), 89.
4) G-W. Zhang, S-J. Lai, Y. Yoshimura, and N. Isobe, "Expression of cathelicidins mRNA in the goat mammary gland and effect of the intramammary infusion of lipopolysaccharide on milk cathelicidin-2 concentration"Vet. Microbiol.., 2014, 170, (1-2), 125.
5) H. Tateno, S. Saito, K. Hiemori, K. Kiyoi, K. Hasehira, M. Toyoda, Y. Onuma, Y. Ito, H. Akutsu, and J. Hirabayashi, "α2–6 sialylation is a marker of the differentiation potential of human mesenchymal stem cells"Glycobiology., 2016, 26, (12), 1328.
6) K. Iizumi, H. Kawasaki, A. Shigenaga, M. Tominaga, A. Otsu, A. Kamo, Y. Kamata, K. Takamori, and F. Yamakura, "Tryptophan nitration of immunoglobulin light chain as a new possible biomarker for atopic dermatitis"J Clin Biochem Nutr., 2018, 63, (3), 197.
7) K. Morioka, K. Fukai, K. Yoshida, R. Yamazoe, H. Onozato, S. Ohashi, T. Tsuda, and K. Sakamoto, "Foot-and-Mouth Disease Virus Antigen Detection Enzyme-Linked Immunosorbent Assay Using Multiserotype-Reactive Monoclonal Antibodies"J. Clin. Microbiol.., 2009, 47, (11), 3663.
8) M. Watanabe, I. Takemasa, N. Kaneko, Y. Yokoyama, E. Matsuo, S. Iwasa, M. Mori, N. Matsuura, M. Monden, and O. Nishimura, "Clinical significance of circulating galectins as colorectal cancer markers"Oncol. Rep.., 2011, 25, (5), 1217.
9) M. Yasunaga, S. Saijou, S. Hanaoka, T. Anzai, R. Tsumura, and Y. Matsumura, "Significant antitumor effect of an antibody against TMEM180, a new colorectal cancer‐specific molecule"Cancer Sci.., 2019, 110, (2), 761.
10) N. Esaki, Y. Ohkawa, N. Hashimoto, Y. Tsuda, Y. Ohmi, R. H. Bhuiyan, N. Kotani, K. Honke, A. Enomoto, M. Takahashi, K. Furukawa, and K. Furukawa, "ASC amino acid transporter 2, defined by enzyme‐mediated activation of radical sources, enhances malignancy of GD2‐positive small‐cell lung cancer"Cancer Sci.., 2018, 109, (1), 141.
11) N. Hashimoto, K. Hamamura, N. Kotani, K. Furukawa, K. Kaneko, K. Honke, and K. Furukawa, "Proteomic analysis of ganglioside‐associated membrane molecules: Substantial basis for molecular clustering"Proteomics., 2012, 12, (21), 3154.
12) N. Kotani, Y. Ida, T. Nakano, I. Sato, R. Kuwahara, A. Yamaguchi, M. Tomita, K. Honke, and T. Murakoshi, "Tumor-dependent secretion of close homolog of L1 results in elevation of its circulating level in mouse model for human lung tumor"Biochem. Biophys. Res. Commun.., 2018, 501, (4), 982.
13) R. Yamashita, N. Kotani, Y. Ishiura, S. Higashiyama, and K. Honke, "Spatiotemporally-regulated interaction between β1 integrin and ErbB4 that is involved in fibronectin-dependent cell migration"J. Biol. Chem.., 2011, 149, (3), 347.
14) T. Noro, E. Oishi, T. Kaneshige, K. Yaguchi, K. Amimoto, and M. Shimizu, "Identification and characterization of haemagglutinin epitopes of Avibacterium paragallinarum serovar C"Vet. Microbiol.., 2008, 131, (3-4), 406.
15) K. Okada, H. Itoh and M. Ikemotob, "Circulating S100A8/A9 is potentially a biomarker that could reflect the severity of experimental colitis in rats', Heliyon, 2020, 6, (2), e03470.

Q & A

Q

Can I use this kit for F(ab')2

A

Yes, please follow the labeling protocol for IgG. The recovery of the conjugate should be over 80%.

Q

Can I use this kit for other proteins or peptides?

A

Yes, if the molecular weight of the reduced form is greater than 50,000 or less than 5,000, and it has a reactive SH group, or a disulfide group that can be reduced without losing activity. If the molecular weight is greater than 50,000, follow the labeling protocol for IgG, and use 0.5-1 nmol of sample protein for LK09-10. If the molecular weight is less than 5,000, follow the labeling protocol for small molecules. If the molecular weight is between 5,000 and 50,000, contact our customer service for more information.

Q

Can I use this kit to label oligopeptides or oligonucleotides?

A

Yes, if the molecular weights of the oligonucleotide or the oligopeptide are less than 5,000 and they have at least one SH group. Follow the labeling protocol for small molecule.

Q

What is the minimum amount of IgG that can be labeled with LK09

A

The minimum amount is 50 μg. There is no significant difference in sensitivity and background between 50 μg and 200 μg of IgG. However, even 10 μg IgG can be labeled using 1/5 volume of SH-reactive peroxidase solution at Step 8.

Q

How many peroxidase molecules per reduced IgG are introduced?

A

The average number of peroxidase molecule per reduced IgG is 1 to 2.

Q

Do I have to use a Filtration tube prior to labeling the protein?

A

If the protein solution does not contain small molecules with reactive SH groups and the concentration of the protein is 10 mg per ml, or about 70 μM, there is no need to use the Filtration tube. Just mix the sample solution with Solution B and add the mixture to a vial of the SH-reactive peroxidase.

Q

Do I have to use Storage buffer included with the kit?

A

No, you don’t have to use Storage buffer from the kit. You can choose any kind of buffer appropriate for your experiment. However, the Storage buffer helps to increase the stability of the peroxidase conjugate.

Q

My sample contains small insoluble material. What should I do?

A

Spin the sample and use the supernatant for labeling.

Q

Does unconjugated SH reactive peroxidase still have a reactive maleimide after the labeling reaction to IgG?

A

No. Nearly 100% of SH reactive peroxidase is used for the IgG labeling or the small molecule labeling.

Q

Does Storage buffer contain animal products or polymers?

A

No, Storage buffer does not contain any animal products, polymers, or heavy metal ions.

Handling and storage condition

Handling and storage condition
0-5°C, Protect from moisture
Danger / harmful
symbol mark
感嘆符
Contact
Price

Product Classification

Product Classification

Search word